Cometriq and Deep venous thrombosis - a phase IV clinical study of FDA data

Summary:

Deep venous thrombosis is reported as a side effect among people who take Cometriq (cabozantinib s-malate), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Keppra, and have Lung neoplasm malignant.

The phase IV clinical study analyzes which people have Deep venous thrombosis when taking Cometriq. It is created by eHealthMe based on reports of 2,712 people who have side effects when taking Cometriq from the FDA, and is updated regularly.

What is Cometriq?

Cometriq has active ingredients of cabozantinib s-malate. eHealthMe is studying from 2,712 Cometriq users. Check the latest studies of Cometriq.

What is Deep venous thrombosis?

Deep venous thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis) is found to be associated with 2,059 drugs and 2,968 conditions by eHealthMe. Check the latest studies of Deep venous thrombosis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

2,712 people reported to have side effects when taking Cometriq.
Among them, 13 people (0.48%) have Deep venous thrombosis.

Could Cometriq cause Deep venous thrombosis?

Among these 13 people:

How long have people been on Cometriq when they have Deep venous thrombosis? *

What is the gender of people who have Deep venous thrombosis when taking Cometriq? *

female: 23.08 %
male: 76.92 %

What is the age of people who have Deep venous thrombosis when taking Cometriq? *

What are other drugs people take besides Cometriq? *

What are other side effects people have besides Deep venous thrombosis? *

Malignant Neoplasm Progression (cancer tumour came back): 6 people, 46.15%
Pulmonary Embolism (blockage of the main artery of the lung): 4 people, 30.77%
Weakness: 3 people, 23.08%
Swallowing Difficulty: 3 people, 23.08%
Nausea And Vomiting: 3 people, 23.08%
Nausea (feeling of having an urge to vomit): 2 people, 15.38%
Bone Pain: 2 people, 15.38%
Diarrhea: 2 people, 15.38%
Eye Pain: 1 person, 7.69%
Feeling Abnormal: 1 person, 7.69%

What are the existing conditions these people have? *

Thyroid Cancer: 3 people, 23.08%
Renal Cell Carcinoma (a kidney cancer): 3 people, 23.08%
Medullary Thyroid Cancer (type of thyroid cancer that develops in the parafollicular cells of the thyroid gland): 3 people, 23.08%
Lung Neoplasm Malignant (cancer tumour of lung): 3 people, 23.08%
Prostate Cancer: 1 person, 7.69%
Neoplasm Malignant (cancer tumour): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Cometriq and have Deep venous thrombosis?

- Check whether Deep venous thrombosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cometriq:

Cometriq (2,712 reports)

Browse all side effects of Cometriq:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Deep venous thrombosis:

Deep venous thrombosis (2,059 drugs)

Browse all the conditions that are associated with Deep venous thrombosis:

Deep venous thrombosis (2,968 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on cabozantinib s-malate (the active ingredients of Cometriq) and Cometriq (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.